BD 1047
Latest Information Update: 26 Apr 2002
Price :
$50 *
At a glance
- Originator Nonindustrial sources
- Class Antiparkinsonians; Neuroprotectants
- Mechanism of Action Sigma receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cocaine-related disorders
Most Recent Events
- 15 Nov 1999 New profile
- 15 Nov 1999 Preclinical development for Cocaine abuse in USA (Unknown route)